Risk stratification and role for additional diagnostic testing in patients with acute chest pain and normal high-sensitivity cardiac troponin levels

PLoS One. 2018 Sep 7;13(9):e0203506. doi: 10.1371/journal.pone.0203506. eCollection 2018.

Abstract

Background: Normal high sensitivity cardiac troponin (hs-cTn) assays rule out acute myocardial infarction (AMI) with great accuracy, but additional non-invasive testing is frequently ordered. This observational study evaluates whether clinical characteristics can contribute to risk stratification and could guide referral for additional testing.

Methods: 918 serial patients with acute chest pain and normal hs-cTnT levels were prospectively included. Major adverse cardiac events (MACE) and non-invasive test results were assessed during one-year follow-up. Patients were classified as low and high risk based on clinical characteristics.

Results: MACE occurred in 6.1% of patients and mainly comprised revascularizations (86%). A recent abnormal stress test, suspicious history, a positive family history and higher baseline hs-cTnT levels were independent predictors of MACE with odds ratios of 16.00 (95%CI:6.25-40.96), 16.43 (6.36-42.45), 2.33 (1.22-4.42) and 1.10 (1.01-1.21), respectively. Absence of both recent abnormal stress test and suspicious history identified 86% of patients. These patients were at very low risk for MACE (0.4% in 30-days and 2.3% in one-year). Despite this, the majority (287/345 = 83%) of additional tests were performed in low risk patients, with <10% abnormal test findings. The diagnostic yield was significantly higher in the remaining higher risk patients, 40% abnormal test findings and a positive predictive value of 70% for MACE. Similar results were observed in patients without known coronary artery disease.

Conclusions: Clinical characteristics can be used to identify low risk patients with acute chest pain and normal hs-cTnT levels. Current strategies in the emergency department result in numerous additional tests, which are mostly ordered in patients at very low risk and have a low diagnostic yield.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Chest Pain / diagnosis*
  • Diagnostic Tests, Routine / methods*
  • Emergency Service, Hospital
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnosis*
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Troponin T / analysis*

Substances

  • Troponin T

Grants and funding

This work was supported by the Netherlands Heart Foundation [grant number 2014T051 to MWS]. Dr. Bekkers, Dr Kietselaer and Dr. Wildberger report funding from The Weijerhorst foundation. Prof. Dr. Wildberger reports institutional grants from Siemens, Philips, GE, Bayer, AGFA, personal fees (speaker's bureau) from Siemens, GE and Bayer outside the submitted work. Dr. Kietselaer reports unrestricted grants from Astra Zeneca and Boehringer Ingelheim outside the submitted work. The other authors do not declare any relevant conflicts of interest.